Navigation Links
Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract and Increase Funding for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
Date:10/1/2013

SAN DIEGO, Oct. 1, 2013 /PRNewswire/ -- Pfenex Inc. today announced that the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA), has modified its prime contract and simultaneously exercised an option associated with the existing Pfenex contractual relationship begun in July, 2010. This extends the prime contract and increases the funding to support the development of a next generation rPA-based anthrax vaccine based on rPA produced in its platform technology, Pfēnex Expression Technology™.  The increase in funding of approximately $8.0 million brings the total funding available to approximately $23.9 million over the course of the contract if all options are exercised. During the contract's base period, Pfenex demonstrated that a strongly immunogenic, stable and protective form of rPA could be expressed and recovered from the highly efficient fermentation of a strain of P. fluorescens engineered to produce rPAThe exercise of this option allows for the completion of preclinical studies, implementation of analytical methods and cGMP manufacturing.

"We are pleased with the results and progress provided by Pfenex's recombinant platform technology to the production of a next generation anthrax vaccine," stated Bertrand C. Liang, Chief Executive Officer. "The exercise of this option and increase in funding by BARDA enables Pfenex and BARDA to continue our successful partnership sharing a common objective to develop an anthrax vaccine with a process capable of achieving the goals of the Strategic National Stockpile for the U. S. Government, including production, shelf life, and administration improvements."

About Pfenex Inc.  
Pfenex Inc. is a biotechnology company developing biosimilars and innovative vaccines to address unmet and growing global healthcare needs.  Utilizing the company's core technology, Pfēnex Expression Technology™ for recombinant protein expression, Pfenex is able to rapidly develop and produce high quality biopharmaceuticals. In addition, Pfenex also produces and markets research proteins and reagent proteins for the research and drug development community through its Reagent Proteins division.  For more information please visit www.pfenex.com 


'/>"/>
SOURCE Pfenex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Nuisance seaweed found to produce compounds with biomedical potential
2. MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012
3. UMass Medical School scientist named 2012 Pew Latin-American Fellow in the Biomedical Sciences
4. 22 of Americas most promising scientists selected as Pew Biomedical Scholars
5. Top young Latin-American scientists named Pew Biomedical Fellows
6. Saladax Biomedical Enters into Master Collaboration Agreement with Bristol-Myers Squibb
7. BGI Tech and BAB jointly develop transgenic mice platform for biomedical research
8. Reproducibility Initiative to increase the value of biomedical research
9. £30 million boost for biomedical engineering research
10. MU celebrates $5 million partnership for advancing biomedical discoveries
11. CNIO participates in the ENCODE project: A stride forward in biomedical research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... to 2025" report to their offering. ... The Global Biometric Vehicle Access System Market ... the next decade to reach approximately $1,580 million by 2025. ... for all the given segments on global as well as regional ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ... it will be hosting a Webinar titled, “Pathology is going digital. Is your ... on digital pathology adoption best practices and how Proscia improves lab economics and ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... International research firm Parks Associates announced today that Tom ... 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series ... 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population ... challenge of how to continue to feed a growing nation. At the same time, ...
Breaking Biology Technology: